A Network-based Drug Repositioning Infrastructure for Precision Cancer Medicine Through Targeting Significantly Mutated Genes in the Human Cancer Genomes

Overview

Journal J Am Med Inform Assoc

Publisher Oxford University Press

Specialty Medical Informatics

Date 2016 Mar 31

PMID 27026610

Citations 28

Authors

Feixiong Cheng

Junfei Zhao

Michaela Fooksa

Zhongming Zhao

Affiliations

Soon will be listed here.

Abstract

Objective: Development of computational approaches and tools to effectively integrate multidomain data is urgently needed for the development of newly targeted cancer therapeutics.

Methods: We proposed an integrative network-based infrastructure to identify new druggable targets and anticancer indications for existing drugs through targeting significantly mutated genes (SMGs) discovered in the human cancer genomes. The underlying assumption is that a drug would have a high potential for anticancer indication if its up-/down-regulated genes from the Connectivity Map tended to be SMGs or their neighbors in the human protein interaction network.

Results: We assembled and curated 693 SMGs in 29 cancer types and found 121 proteins currently targeted by known anticancer or noncancer (repurposed) drugs. We found that the approved or experimental cancer drugs could potentially target these SMGs in 33.3% of the mutated cancer samples, and this number increased to 68.0% by drug repositioning through surveying exome-sequencing data in approximately 5000 normal-tumor pairs from The Cancer Genome Atlas. Furthermore, we identified 284 potential new indications connecting 28 cancer types and 48 existing drugs (adjusted P < .05), with a 66.7% success rate validated by literature data. Several existing drugs (e.g., niclosamide, valproic acid, captopril, and resveratrol) were predicted to have potential indications for multiple cancer types. Finally, we used integrative analysis to showcase a potential mechanism-of-action for resveratrol in breast and lung cancer treatment whereby it targets several SMGs (ARNTL, ASPM, CTTN, EIF4G1, FOXP1, and STIP1).

Conclusions: In summary, we demonstrated that our integrative network-based infrastructure is a promising strategy to identify potential druggable targets and uncover new indications for existing drugs to speed up molecularly targeted cancer therapeutics.

Citing Articles

as a Prognostic Biomarker: Linking Copy Number Variation to EMT and Survival in Colon Cancer.

Bang H, Shim H, Park M, Yoon S, Yoo K, Kim Y Int J Mol Sci. 2024; 25(21).

PMID: 39518976 PMC: 11546699. DOI: 10.3390/ijms252111423.

BETA: a comprehensive benchmark for computational drug-target prediction.

Zong N, Li N, Wen A, Ngo V, Yu Y, Huang M Brief Bioinform. 2022; 23(4).

PMID: 35649342 PMC: 9294420. DOI: 10.1093/bib/bbac199.

Pan-cancer analyses reveal the genetic and pharmacogenomic landscape of transient receptor potential channels.

Pan T, Gao Y, Xu G, Zhou P, Li S, Guo J NPJ Genom Med. 2022; 7(1):32.

PMID: 35614079 PMC: 9132893. DOI: 10.1038/s41525-022-00304-1.

Artificial intelligence in cancer target identification and drug discovery.

You Y, Lai X, Pan Y, Zheng H, Vera J, Liu S Signal Transduct Target Ther. 2022; 7(1):156.

PMID: 35538061 PMC: 9090746. DOI: 10.1038/s41392-022-00994-0.

Overexpression of abnormal spindle-like microcephaly-associated (ASPM) increases tumor aggressiveness and predicts poor outcome in patients with lung adenocarcinoma.

Feng Z, Zhang J, Zheng Y, Liu J, Duan T, Tian T Transl Cancer Res. 2022; 10(2):983-997.

PMID: 35116426 PMC: 8798794. DOI: 10.21037/tcr-20-2570.

References

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

Kramer O, Zhu P, Ostendorff H, Golebiewski M, Tiefenbach J, Peters M . The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003; 22(13):3411-20. PMC: 165640. DOI: 10.1093/emboj/cdg315. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

Bodenreider O . The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2003; 32(Database issue):D267-70. PMC: 308795. DOI: 10.1093/nar/gkh061. View

Ylisastigui L, Archin N, Lehrman G, Bosch R, Margolis D . Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS. 2004; 18(8):1101-8. DOI: 10.1097/00002030-200405210-00003. View

Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A . An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38):13550-5. PMC: 1197273. DOI: 10.1073/pnas.0506230102. View

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor J . Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006; 66(15):7466-72. DOI: 10.1158/0008-5472.CAN-06-1191. View

Lamb J, Crawford E, Peck D, Modell J, Blat I, Wrobel M . The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313(5795):1929-35. DOI: 10.1126/science.1132939. View

10.

Hernandez-Boussard T, Whirl-Carrillo M, Hebert J, Gong L, Owen R, Gong M . The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 2007; 36(Database issue):D913-8. PMC: 2238877. DOI: 10.1093/nar/gkm1009. View

11.

Croce C . Oncogenes and cancer. N Engl J Med. 2008; 358(5):502-11. DOI: 10.1056/NEJMra072367. View

12.

Tang F, Su Y, Chen N, Hsieh H, Chen K . Resveratrol inhibits migration and invasion of human breast-cancer cells. Mol Nutr Food Res. 2008; 52(6):683-91. DOI: 10.1002/mnfr.200700325. View

13.

Kothare S, Kaleyias J . Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008; 4(4):493-506. DOI: 10.1517/17425255.4.4.493. View

14.

Attoub S, Gaben A, Al-Salam S, Al Sultan M, John A, Nicholls M . Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci. 2008; 1138:65-72. DOI: 10.1196/annals.1414.011. View

15.

Hopkins A . Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682-90. DOI: 10.1038/nchembio.118. View

16.

Rajamani S, Shryock J, Belardinelli L . Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin). 2008; 2(6):449-60. DOI: 10.4161/chan.2.6.7362. View

17.

Roepman P, Jassem J, Smit E, Muley T, Niklinski J, van de Velde T . An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res. 2009; 15(1):284-90. DOI: 10.1158/1078-0432.CCR-08-1258. View

18.

Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W . IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. PMC: 2820383. DOI: 10.1056/NEJMoa0808710. View

19.

Knight Z, Lin H, Shokat K . Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010; 10(2):130-7. PMC: 2880454. DOI: 10.1038/nrc2787. View

20.

Denny J, Ritchie M, Basford M, Pulley J, Bastarache L, Brown-Gentry K . PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010; 26(9):1205-10. PMC: 2859132. DOI: 10.1093/bioinformatics/btq126. View